Abstract. Berberine (BBR) is an isoquinoline alkaloid which has a wide spectrum of clinical applications including antitumor, anti-microbial and anti-inflammatory activities. In this study, we showed that co-treatment with subtoxic doses of BBR and tumor necrosis factor-related apoptosis-inducing ligand ( 
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potential new anticancer drug. TRAIL induces apoptosis in various types of cancer cells in vitro and in vivo, but has little or no toxicity against normal cells, which is supported by the presence of large numbers of decoy receptors on normal cells (1, 2) . A soluble recombinant TRAIL is undergoing a phase I clinical trial for the treatment of solid tumors (3) . However, recent studies have shown that some cancer cells are resistant to the apoptotic effects of TRAIL (4) (5) (6) , indicating that the single treatment with TRAIL may be insufficient for cancer therapy. Some studies demonstrated that several dietary compounds including resveratrol (6) , withaferin A (7), and curcumin (8) sensitize different cancer cells to TRAIL-mediated apoptosis.
Berberine (BBR), a natural alkaloid, is isolated from many medicinal herbs, such as the Chinese herb Huanglian, berberis aquifolium, and berberis vulgaris (9) . It has been shown to exhibit multiple pharmacological activities such as inhibition of DNA synthesis, G1 cell cycle arrest, and anticancer effect (10, 11) . BBR has been reported to inhibit expression of cyclooxygenase-2 (COX-2), to exert anti-metastatic properties in non-small lung cancer cells, as well as to induce apoptosis via promoting the expression of caspase, apoptosisinducing factor (AIF) and endonuclease G in human tongue squamous carcinoma cancer cells (12) . In addition, BBR also sensitizes human glioma cells to ionizing radiation in vitro (13) . It was also reported that co-administration with BBR and doxorubicin in xenografted human tongue squamous carcinoma cancer reduced tumor growth at the concentration of doxorubicin without any loss of body weight (14) .
Although a large number of studies also showed that BBR possesses anti-tumor activity, the anti-cancer effect of the combination of BBR and TRAIL is not clear. In the present study, we examined the therapeutic potential of BBR on TRAIL-mediated apoptosis and the potential application of BBR as a complimentary therapeutic agent for human renal cancer cells. DAPI staining. The cells were fixed with 1% paraformaldehyde on slide glass for 30 min at room temperature. After washing with PBS, 300 nM DAPI (40-60-diamidino-2-phenylindole, Roche, Germany) was added to the fixed cells for 5 min, after which they were examined by fluorescence microscopy. Apoptotic cells were identified by condensation and fragmentation of nuclei.
Materials and methods

Cells
Measurement of reactive oxygen species. The intracellular accumulation of ROS was determined using the fluorescent probes 2',7'-dichlorodihydrofluorescein diacetate (H 2 DCFDA). Statistical analysis. Three or more separate experiments were performed. Statistical analysis was done by paired Student's t-test or ANOVA. A p<0.05 was considered to have pronounced difference between experimental and control groups.
Results
BBR sensitizes renal cancer cells to TRAIL-mediated apoptosis.
In an attempt to search for novel strategies to overcome TRAIL resistance in cancer cells, we investigated the effect of the combined treatment with BBR and TRAIL in human renal cancer cell line, Caki cell. Co-treatment of Caki cells with BBR and TRAIL resulted in a markedly increased accumulation of sub-G1 phase cells, compared with Caki cells treated with BBR or TRAIL alone (Fig. 1A) . In addition, the combined treatment of Caki cells with BBR and TRAIL strongly led to a reduction of the protein levels of 32-kDa precursor together with a concomitant cleavage of PARP, a substrate protein of caspases (Fig. 1B) . Next, we analyzed nuclear condensation, which is another hallmark of apoptosis. Combinational treatment with BBR plus TRAIL induced the nuclear condensation in Caki cells. In contrast, nuclear condensation in Caki cells treated with TRAIL alone or BBR alone was barely detected (Fig. 1C) . To examine whether cotreatment with BBR and TRAIL affected renal cancer ACHN cells, we investigated the effect of the combined treatment with BBR and TRAIL in ACHN cell. Co-treatment of ACHN cells with BBR and TRAIL resulted in a markedly increased accumulation of sub-G1 phase cells, compared with Caki cells treated with BBR or TRAIL alone (Fig. 1D) . Next, we investigated whether co-treatment with BBR and TRAIL affected TCMK-1 normal renal tubular epithelial cell. Interestingly, TCMK-1 cells were resistant to 60 μM BBR or 100 ng/ml TRAIL alone, and cell morphologies were not significantly affected by treatment with a combination of 60 μM BBR and 100 ng/ml TRAIL (Fig. 1E) . Cells were treated with the indicated concentrations of BBR and TRAIL. Equal amounts of cell lysates (40 μg) were subjected to electrophoresis and analyzed by Western blot analysis for PARP, pro-caspase-3, and actin for normalization. (C) After treatment with BBR plus and TRAIL for 24 h, cells were harvested and washed with PBS and exposed to 300 nM 4',6-diamidino-2-phenylindole (DAPI) at room temperature in the dark for 15 min. Samples were observed under a fluorescence microscope. The healthy cell had an oval-shaped cell body, and its chromatin stained dimly and occupied the majority of the cell body. The chromatin of an apoptotic cell was condensed, intensely stained, or shifted to the periphery of the cell body. The morphologies of cells were determined by interference light microscopy (magnification, x200). (D) ACHN cells were treated for 24 h with TRAIL (100 ng/ml) in either the absence or the presence of BBR (60 μM). After 24 h of treatment, apoptosis was analyzed as a sub-G1 fraction by FACS. a p<0.05 for BBR+TRAIL-treated cells versus control, BBR-, or TRAIL-treated cells by ANOVA. (E) Mouse tubular normal TCMK-1 cells were treated for 24 h with TRAIL (100 ng/ml) in either the absence or the presence of BBR (60 μM). After 24 h of treatment, apoptosis was analyzed as a sub-G1 fraction by FACS. Combinational treatment with BBR plus TRAIL-induced apoptosis was mediated by caspase-dependent pathway. We examined whether the activation of caspase pathway plays a critical role in BBR plus TRAIL-induced apoptosis. As shown in Fig. 2A , BBR plus TRAIL-induced apoptosis was completely prevented by pretreatment with a general and potent inhibitor of caspases, z-VAD-fmk, as determined by FACS analysis. These results suggest that the combined treatment with BBR and TRAIL-induced apoptosis was mediated by caspase-dependent apoptosis pathways. We also found that z-VAD-fmk prevented these caspase-related events such as downregulation of procasapse-3 and cleavage of PARP (Fig. 2B) .
BBR downregulates Mcl-1 and c-FLIP protein levels at posttranslational level.
To investigate the underlying mechanisms involved in the combined treatment with BBR and TRAILinduced apoptosis, we analyzed the expression levels of various apoptosis regulating proteins. While protein levels of XIAP, c-FLIP, and Mcl-1 were remarkably reduced in response to BBR plus TRAIL, the levels of death receptor 5 (DR5), c-IAP1, Bcl-2, and Bcl-xL, did not alter (Fig. 3A) . Next, we examined whether the decreased expressions of XIAP, c-FLIP and Mcl-1 proteins were related to caspase activations. Pretreatment with z-VAD-fmk completely recovered XIAP protein to basal level. In contrast, z-VAD-fmk partly blocked BBR plus TRAIL-induced downregulations of (Fig. 3D) . These results suggest the possibility that BBR-mediated degradation of total c-FLIP and Mcl-1 proteins might be regulated by the post-transcriptional levels. (Fig. 4A) , implying that BBR treatment caused reduction of the c-FLIP and Mcl-1 protein stability. Based on this result, we hypothesized that c-FLIP and Mcl-1 proteins would be degraded by the proteasomedependent pathway. To confirm this hypothesis, we treated the cells with the proteasome inhibitor MG132. Caki cells were treated with BBR (60 μM) plus CHX in the absence or presence of MG132 (0.5 μM). As expected, the decreased protein levels of c-FLIP and Mcl-1 in BBR-treated Caki cells were almost recovered to basal levels by MG132 treatment (Fig. 4B) .
Decreased expressions of c-FLIP and
BBR-stimulated TRAIL-induced apoptosis appears to be dependent on the formation of reactive oxygen species (ROS) via the downregulation of c-FLIP and Mcl-1.
Numerous investigations have documented that ROS may play an important role during apoptosis induction (15, 16) . It has been reported that BBR increases ROS production in various cancer cells (10, 17, 18) . Therefore, we examined whether ROS generation might be involved in BBR plus TRAILinduced apoptosis. H 2 DCFDA-based fluorescence microscope detection showed that treatment of Caki cells with BBR increased intracellular ROS levels, which were prevented by anti-oxidant N-acetyl-L-cysteine (NAC) pretreatment (Fig. 5A) . We next investigated whether ROS generation is directly associated with BBR plus TRAIL-induced apoptosis. As shown in Fig. 5B , pretreatment with NAC markedly blocked BBR plus TRAIL-induced apoptosis. However, NAC pretreatment recovered the decreased expression levels of c-FLIP by BBR treatment to basal levels, BBR-induced downregulation of Mcl-1 protein was partly blocked by NAC treatment (Fig. 5C ). These results suggest the possibility that BBR-stimulated downregulation of c-FLIP protein appears to be dependent on the generation of reactive oxygen species for downregulation of c-FLIP through proteasomal activation.
Discussion
In the present study, we demonstrate for the first time that treatment of renal cancer cells with BBR in combination with TRAIL synergistically induced apoptosis. c-FLIP and Mcl-1 were downregulated when BBR and TRAIL were administered together, which was caused by facilitating degradation of c-FLIP and Mcl-1 proteins. In addition, we also found that treatment with BBR in combination with TRAIL of Caki cells led to ROS generation, as shown using the fluorescent dyes, H 2 DCFDA, which production of ROS by BBR treatment seems to be critical for c-FLIP and Mcl-1 downregulation. Furthermore, combinatory treatment with BBR plus TRAIL synergistically enhanced apoptosis in renal cancer ACHN cells without any cytotoxicity in normal tubular kidney cells.
Several studies demonstrate that TRAIL almost selectively induces apoptosis in cancer cells with no or minimal toxicity on non-neoplastic cells (1, 5) . However, treatment with TRAIL alone may be insufficient for cancer therapy because some cancers display resistance to TRAIL. In addition, regular consumption of natural compounds such as tea, herbs, gingers, and spices is associated with reduced risk of cancer (19, 20) . Therefore, much effort to improve the survival of cancer patients also focus on the search for natural compounds for treatment of cancer to escape TRAIL resistance or to sensitize cancer cells to TRAIL-induced apoptosis.
Induction of DR5 expression is an important mechanism underlying sensitization of TRAIL-mediated apoptosis (21) (22) (23) (24) (25) . In this study, we failed to detect any induction of DR5 expression in BBR-treated Caki cells, indicating that DR5 modulation has a restricted role in BBR-induced sensitization of TRAILprompted apoptosis in these cells. Several natural compounds such as triterpenoids, silibinin, and flavopiridol can induce downregulation of c-FLIP and subsequent sensitization to TRAIL-induced apoptosis in cancer cells (26, 27) . In our present study, treatment with BBR induced downregulation of c-FLIP and the transient expression of c-FLIP partly abrogated induction of apoptosis by combined treatment with BBR and TRAIL (data not shown). These results suggested a critical role of c-FLIP downregulation in mediating the augmentation of TRAIL-induced apoptosis by BBR. It is generally recognized that c-FLIP protein levels can be transcriptionally regulated through the NF-κB or c-Fos pathway (28, 29) , or by ubiquitin/proteasome-mediated degradation (30) (31) (32) . In this study, we found that BBR promotes ubiquitin/proteasome-mediated degradation of c-FLIP, leading to downregulation of c-FLIP, but not by transcriptional control.
It was reported that BBR induced the ROS-mediated apoptosis and downregulated the expression of Bcl-2 protein in HepG2 cells, which were prevented by NAC treatment (17) . We also found that treatment with BBR induced ROS generation and that pretreatment with NAC prevented BBR plus TRAIL-induced apoptosis. Contrary to this report, we failed to detect any change in Bcl-2 protein levels but found marked change of Mcl-1 protein levels by BBR treatment in our system. This controversial result might reflect the differences in the signaling pathways depending on the cellular contexts. Recently, several studies have shown that ROS downregulated c-FLIP or Mcl-1 levels and increased the sensitivity to apoptotic stimuli (33) (34) (35) . Therefore, we investigated whether downregulation of c-FLIP and Mcl-1 was actually mediated by ROS signaling pathway. In the presence of NAC, the decreased levels of c-FLIP and Mcl-1 caused by BBR were restored. Taken together, BBRstimulated TRAIL-induced apoptosis appears to be dependent on the formation of ROS for downregulation of c-FLIP and Mcl-1 proteins. BBR triggered a proteasomal proteolytic pathway which enhanced protein degradation such as HIF-1ß degradation (36) . Parallel to this observation, we observed that BBR triggered c-FLIP and Mcl-1 degradation through a proteasomal proteolytic pathway. However, further study is needed for the mechanistic study to elucidate BBR-induced activation of proteasomal signaling pathway.
In summary, our results provide the first mechanistic evidence that BBR treatment results in ROS-mediated downregulation of c-FLIP and Mcl-1, rendering cancer cells more sensitive to TRAIL. In addition, we suggest that BBR may be a potentially important therapeutic approach for enhancing sensitivity to TRAIL via the inhibition of anti-apoptotic proteins, such as c-FLIP and Mcl-1 in human renal cancer.
